Efficacy News and Research

RSS

Study may allow more patients to benefit from transcatheter aortic valve replacement

The Society of Thoracic Surgeons (STS) has launched an investigational study with the American College of Cardiology (ACC) that may allow more patients to benefit from transcatheter aortic valve replacement (TAVR), a minimally invasive procedure that delivers a replacement heart valve via a catheter.

18 Jul 2013

Drug that spurs cancer cells to self-destruct is on road to human clinical trials

Thanks to a new $2 million investment, a drug that spurs cancer cells to self-destruct while sparing healthy cells is on the road to human clinical trials. The compound, known as PAC-1, has so far proven safe and has promising anti-cancer effects in cell culture, in mouse models of cancer and in pet dogs with spontaneously occurring lymphomas and osteosarcomas.

18 Jul 2013

Rexahn Pharmaceuticals signs license agreement with UMB for novel drug delivery platform

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, announced today that it has signed an exclusive license agreement with the University of Maryland, Baltimore for a novel drug delivery platform, Nano-Polymer-Drug Conjugate Systems.

17 Jul 2013

Adynxx receives FDA Fast Track designation for AYX1 Injection to treat chronic pain

Adynxx, a clinical-stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the U.S. Food and Drug Administration has granted Fast Track designation to AYX1 Injection for the prevention of chronic pain.

17 Jul 2013

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that, through a wholly-owned subsidiary, the company entered into an agreement to acquire Talon Therapeutics, Inc., a biopharmaceutical company based in South San Francisco, California, and expects to complete the acquisition within one day.

17 Jul 2013

Sequella licenses Pfizer's exclusive worldwide rights to develop, commercialize sutezolid

Sequella, a clinical-stage pharmaceutical company commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it has licensed Pfizer Inc's exclusive worldwide rights to develop and commercialize sutezolid, a Phase 2 oxazolidinone antibiotic currently in development for the treatment of tuberculosis.

17 Jul 2013

Combination therapy during cardiac arrest results in improved hospital discharge and neurological status

Among patients who experienced in-hospital cardiac arrest requiring vasopressors (drugs that increase blood pressure), use of a combination therapy during cardiopulmonary resuscitation resulted in improved survival to hospital discharge with favorable neurological status, according to a study in the July 17 issue of JAMA.

17 Jul 2013

FDA accepts Iroko's submicron indomethacin NDA for treatment of acute pain in adults

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to scientific advancements in analgesia, announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application for lower dose submicron indomethacin, a non-steroidal anti-inflammatory drug, for the proposed indication of treatment of mild to moderate acute pain in adults.

16 Jul 2013

Furiex Pharmaceuticals enrolls patient for Phase III clinical trial of eluxadoline for treatment of diarrhea

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced completion of patient enrollment in the company's two ongoing Phase III clinical trials studying eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome, or IBS-d. Both studies met their target enrollments and Furiex expects to release top line results in the first quarter of 2014.

16 Jul 2013

Study shows flavonoid-based nutritional supplements can affect endocrine system

Plant-based diets are healthy. Plants are high in flavonoids. So flavonoids are healthy. At least that's the reasoning of many manufacturers of flavonoid-based nutritional supplements.

16 Jul 2013

ADC Therapeutics, BZL Biologics sign licensing deal for antibody against PSMA-positive prostate cancers

ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates, and BZL Biologics LLC, of New York, today announced an exclusive licensing and collaboration agreement for an antibody against PSMA-positive prostate cancers.

15 Jul 2013

Clinical trial begins on ultrasound in combination with tPA to treat acute ischemic stroke

An international, Phase III clinical trial studying ultrasound in combination with a clot-busting medication to treat acute ischemic stroke has begun at The University of Texas Health Science Center at Houston (UTHealth).

12 Jul 2013

Auspex enrolls first patient in SD-809 Phase 3 trial for treatment of chorea associated with HD

Auspex Pharmaceuticals announced today that the first patient has been enrolled in a multi-center Phase 3 pivotal trial of its lead investigational drug, SD-809 for the treatment of involuntary movements (chorea) associated with Huntington's Disease.

12 Jul 2013

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that its phase III study (MM-020/IFM 07-01) of REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival.

11 Jul 2013

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration has accepted for review a Supplemental New Drug Application for Eliquis (apixaban), for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in adult patients who have undergone hip or knee replacement surgery.

11 Jul 2013

Research on activating Glial Cells to be presented at 7th Annual Pain Therapeutics Summit East

Linda Watkins, Ph.D., Distinguished Professor, Department of Psychology & Neuroscience and Center for Neuroscience, University of Colorado, Co-Chair, Advisory Board, Xalud Therapeutics, Inc. will present research on activating Glial Cells as part of the speaking faculty at the 7th Annual Pain Therapeutics Summit East in Boston, MA.

11 Jul 2013

New method to identify pathogenic strains that cause pneumonia

Researchers from Boston University School of Medicine (BUSM) and George Washington University (GWU) have developed a method to rapidly identify pathogenic species and strains causing illnesses, such as pneumonia, that could help lead to earlier detection of disease outbreaks and pinpoint effective treatments more quickly.

11 Jul 2013

Robotic retroperitoneal lymph node dissection (RPLND) for testicular cancer: an interview with Dr. Stephen Williams of St. Joseph Hospital in Orange

Robotic RPLND utilizes laparoscopy combined with robotic technology to perform dissection and removal of lymph node tissue in the retroperitoneum both as a staging as well as therapeutic procedure for patients with testicular cancer.

10 Jul 2013

Ohr Pharmaceutical enrolls first 60 patients in OHR-002 Phase II clinical trial for wet-AMD treatment

Ohr Pharmaceutical, Inc., a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that it has enrolled the first 60 patients in the Company's ongoing OHR-002 Phase II clinical trial evaluating Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration.

10 Jul 2013

New approach delivers RNA drugs to silence malfunctioning genes

Silencing genes that have malfunctioned is an important approach for treating diseases such as cancer and heart disease. One effective approach is to deliver drugs made from small molecules of ribonucleic acid, or RNA, which are used to inhibit gene expression. The drugs, in essence, mimic a natural process called RNA interference.

10 Jul 2013

Efficacy News and Research

Study may allow more patients to benefit from transcatheter aortic valve replacement

Drug that spurs cancer cells to self-destruct is on road to human clinical trials

Rexahn Pharmaceuticals signs license agreement with UMB for novel drug delivery platform

Adynxx receives FDA Fast Track designation for AYX1 Injection to treat chronic pain

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Sequella licenses Pfizer's exclusive worldwide rights to develop, commercialize sutezolid

Combination therapy during cardiac arrest results in improved hospital discharge and neurological status

FDA accepts Iroko's submicron indomethacin NDA for treatment of acute pain in adults

Furiex Pharmaceuticals enrolls patient for Phase III clinical trial of eluxadoline for treatment of diarrhea

Study shows flavonoid-based nutritional supplements can affect endocrine system

ADC Therapeutics, BZL Biologics sign licensing deal for antibody against PSMA-positive prostate cancers

Clinical trial begins on ultrasound in combination with tPA to treat acute ischemic stroke

Auspex enrolls first patient in SD-809 Phase 3 trial for treatment of chorea associated with HD

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Research on activating Glial Cells to be presented at 7th Annual Pain Therapeutics Summit East

New method to identify pathogenic strains that cause pneumonia

Robotic retroperitoneal lymph node dissection (RPLND) for testicular cancer: an interview with Dr. Stephen Williams of St. Joseph Hospital in Orange

Ohr Pharmaceutical enrolls first 60 patients in OHR-002 Phase II clinical trial for wet-AMD treatment

New approach delivers RNA drugs to silence malfunctioning genes

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News